Bio-Bridge says preclinical study of oral HIV vaccine yields promising results

By E. Janene Geiss

Philadelphia, June 16 - Bio-Bridge Science, Inc. said Friday that the Beijing Institute of Radiation Medicine has notified the company that final results of its oral HIV vaccine studies show favorable safety and immunogenicity data.

The studies showed no toxicity in animals administered the vaccine orally, according to a company news release.

The results also show no indication that vaccine DNA integrates into host genome and passes through the placenta barrier, officials said.

The immunogenicity study in monkeys shows that the vaccine induces HIV-1 gp41-specific serum antibodies (IgG) and intestinal and vaginal antibodies (sIgA). The sera, intestinal and vaginal washings neutralize HIV-1 primary isolate in vitro. The vaccine also induces HIV-1 Gag-specific T cells in the vaccinated monkeys, officials said.

Based on these favorable results, the company said it is expected to file application for clinical trials with the Chinese Food and Drug Administration soon.

Bio-Bridge is an Oak Brook, Ill., biotechnology company focused on the development of vaccines with broad therapeutic and preventive applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.